SecBot SecBot

SCYX

SCYNEXIS INC
Nasdaq· Pharmaceutical Preparations· CIK 0001178253 Biotech & Drug Discovery
$2.91 −0.30 (−9.35%)
Nov 16 4:00 PM ET · prev $3.21
Market cap
$33.1M
Nano cap
Median target
$33.00
+1034% · range $32.00–33.00
1 year
−37.0%
from $4.62 · Nov 17
30 days
−20.5%
from $3.66
52-week range
$2.91–8.88
at the low
Avg volume 20D
64.6K
shares / day
Short interest
450.2K
≈4.5% of shares · +7.1%
Days to cover
5.5
at average volume
Insider net
$0.00
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    No open-market sales.

  • InstitutionsMIXED

    Q3 2026: 4 added (0 new), 4 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.720 → −$0.627 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +7.1% to 450.2K shares. 5.5 days to cover, ≈4.5% of shares.

  • TrendDOWNTREND

    30% below its 50-day average. New closing low $2.91 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD419,480$2.1M
GEODE CAPITAL MANAGEMENT, LLCADD120,565$595.7K
RENAISSANCE TECHNOLOGIES LLCTRIM51,825$256.0K
STATE STREET CORPADD23,890$118.0K
UBS Group AGNEAR_EXIT2,721$13.4K
MORGAN STANLEYTRIM2,132$10.5K
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CODOUBLED863$4.3K
BARCLAYS PLCNEAR_EXIT2$10.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +1034%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 13, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Sep 18, 2026
Burke Steven Keith
Director
Sep 18, 2026
AWARD5,750 sh
Sep 18, 2026
Burke Steven Keith
Director
Sep 18, 2026
AWARD5,750 sh
Sep 9, 2026
Subramanian Sanjay
Chief Financial Officer
Sep 9, 2026
AWARD100,000 sh
Jun 26, 2026
HANHAM ANN
Director
Jun 26, 2026
AWARD2,875 sh
Jun 26, 2026
HANHAM ANN
Director
Jun 26, 2026
AWARD2,875 sh
Jun 26, 2026
HASTINGS DAVID C
Director
Jun 26, 2026
AWARD2,875 sh
Jun 26, 2026
HASTINGS DAVID C
Director
Jun 26, 2026
AWARD2,875 sh
Jun 26, 2026
ANIDO ARMANDO
Director
Jun 26, 2026
AWARD2,875 sh

Earnings setup

Estimates
−$0.63
EPS estimate, this quarter
+13%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.63-$0.82–-$0.43+7.2%$237.5K
Next Q-$0.58-$0.69–-$0.38No data$694.5K
Current FY-$3.13-$3.48–-$2.85-7.6%$393.3K
Next FY-$1.95-$2.90–-$0.37+15.6%$9.7M

Short side

FINRA· Oct 30, 2026
450,240
shares short
+7.1%
vs prior settlement
5.5
days to cover
≈4.5%
of shares outstanding
Trading halts
Jul 31, 2026Volatility PauseResumed
Jul 31, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

9 filings · 5 press releases · 0 bullish · 1 bearish · 8 neutral
All SCYX filing & press-release reports (14)